Umer Raffat
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
21
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $35.13 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $5.70 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $2.56 | - | 1 | Feb 28, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | n/a | $2.27 | - | 1 | Feb 16, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $26.59 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $15.89 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical | Upgrades: Outperform | n/a | $18.64 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $18.94 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $13.50 | - | 1 | Mar 7, 2023 | |
| LEGN Legend Biotech | Initiates: Outperform | n/a | $43.61 | - | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $16.92 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.90 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $0.78 | +6,053.85% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $316.91 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,040 | $16.98 | +6,023.95% | 1 | Mar 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $5.32 | +802.26% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $109.41 | - | 1 | Feb 23, 2017 |
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $35.13
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $5.70
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.56
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.27
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $26.59
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.89
Upside: -
Teva Pharmaceutical
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $18.64
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $18.94
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $13.50
Upside: -
Legend Biotech
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $43.61
Upside: -
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $16.92
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.90
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $48
Current: $0.78
Upside: +6,053.85%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $316.91
Upside: -
Mar 19, 2018
Initiates: Outperform
Price Target: $1,040
Current: $16.98
Upside: +6,023.95%
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $5.32
Upside: +802.26%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $109.41
Upside: -